<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Helwick, Caroline</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Wolmark, Norman</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy of Oxaliplatin on Overall and Disease-Free Survival</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">6-7</style></pages><abstract><style  face="normal" font="default" size="100%">The results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 trial [NCT00004931] demonstrated that oxaliplatin prolongs both progression-free and overall survival for patients with stage II or stage III colorectal cancer. The trial was designed to evaluate the efficacy of oxaliplatin when it was added to bolus 5-FU/leucovorin as adjuvant treatment.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>